Can-Fite BioPharma’s (CANF) “Buy” Rating Reiterated at D. Boral Capital

Posted by Casey Walker on Feb 21st, 2025

D. Boral Capital reiterated their buy rating on shares of Can-Fite BioPharma (NYSE:CANF – Free Report) in a research note released on Tuesday,Benzinga reports. They currently have a $10.00 price target on the stock.

A number of other brokerages have also recently weighed in on CANF. StockNews.com began coverage on shares of Can-Fite BioPharma in a research report on Tuesday, February 11th. They set a “sell” rating for the company. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Can-Fite BioPharma in a research report on Tuesday, November 12th.

Check Out Our Latest Report on Can-Fite BioPharma

Can-Fite BioPharma Stock Performance

Shares of CANF opened at $1.91 on Tuesday. Can-Fite BioPharma has a fifty-two week low of $1.29 and a fifty-two week high of $4.69. The stock has a fifty day moving average of $1.54 and a two-hundred day moving average of $1.98. The company has a market capitalization of $5.52 million, a PE ratio of -1.07 and a beta of 1.33.

Hedge Funds Weigh In On Can-Fite BioPharma

An institutional investor recently bought a new position in Can-Fite BioPharma stock. BNP Paribas Financial Markets acquired a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 25,185 shares of the company’s stock, valued at approximately $41,000. BNP Paribas Financial Markets owned about 0.71% of Can-Fite BioPharma at the end of the most recent reporting period. 21.00% of the stock is owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

(Get Free Report)

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.